Slump In Generic Submissions Helps US FDA Draw Nearly Even With Approvals
Agency Publishes Data For First Half Of Current Fiscal Year
The monthly approval rate would be the second-best of the GDUFA era if sustained through the second half of FY 2021 • Source: Alamy 
